CZ343795A3 - Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity - Google Patents

Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity Download PDF

Info

Publication number
CZ343795A3
CZ343795A3 CZ953437A CZ343795A CZ343795A3 CZ 343795 A3 CZ343795 A3 CZ 343795A3 CZ 953437 A CZ953437 A CZ 953437A CZ 343795 A CZ343795 A CZ 343795A CZ 343795 A3 CZ343795 A3 CZ 343795A3
Authority
CZ
Czechia
Prior art keywords
fragment
kgf
growth factor
keratinocyte growth
sequence
Prior art date
Application number
CZ953437A
Other languages
Czech (cs)
English (en)
Inventor
Denis J Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CZ343795A3 publication Critical patent/CZ343795A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
CZ953437A 1993-06-29 1994-04-28 Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity CZ343795A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29

Publications (1)

Publication Number Publication Date
CZ343795A3 true CZ343795A3 (en) 1996-07-17

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ953437A CZ343795A3 (en) 1993-06-29 1994-04-28 Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity

Country Status (25)

Country Link
US (7) US5677278A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1493812A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP3570516B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960703433A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1129955A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE278777T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU681405B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG100236A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407035A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2166278A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ343795A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122006000005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0706563T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2227527T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI956203A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR06C0004I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT73453A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91215I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300217I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO955189L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ266622A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL312257A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT706563E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK153295A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995001434A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
AU647732B2 (en) 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
SK153295A3 (en) * 1993-06-29 1996-11-06 Chiron Corp A truncated keratinocyte growth factor (kgf) having increased biological activity
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
ES2273338T3 (es) * 1994-10-13 2007-05-01 Amgen Inc. Metodo para el tratamiento de la diabetes mellitus usando kfg.
CA2201762C (en) * 1994-10-13 2001-12-18 Eric W. Hsu Method for purifying keratinocyte growth factors
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DK1486565T3 (da) 1995-10-11 2008-03-10 Novartis Vaccines & Diagnostic Kombination af PDGF, KGF, IGF og IGFBP til sårheling
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
CA2294569A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999041282A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
AU2002236477A1 (en) 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
AU2002326742B2 (en) * 2001-08-21 2007-05-31 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CA2589889C (en) * 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP4219708A3 (en) 2009-07-17 2023-10-11 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
KR20240053580A (ko) 2021-08-30 2024-04-24 유니켐 레버러토리스 리미티드 염증성 질환의 치료용 단백질 조성물
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647732B2 (en) * 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
SK153295A3 (en) * 1993-06-29 1996-11-06 Chiron Corp A truncated keratinocyte growth factor (kgf) having increased biological activity
EP0785950B1 (en) 1994-10-13 2003-04-16 Amgen Inc., Keratinocyte growth factor analogs
ES2273338T3 (es) 1994-10-13 2007-05-01 Amgen Inc. Metodo para el tratamiento de la diabetes mellitus usando kfg.

Also Published As

Publication number Publication date
LU91215I2 (en) 2006-03-27
NO955189D0 (no) 1995-12-20
FI956203A0 (fi) 1995-12-22
NZ266622A (en) 1997-10-24
EP0706563A1 (en) 1996-04-17
JP2004166709A (ja) 2004-06-17
DE69434053T2 (de) 2006-02-23
WO1995001434A1 (en) 1995-01-12
DE69434053D1 (de) 2005-01-20
EP1493812A2 (en) 2005-01-05
FR06C0004I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2006-03-10
US6074848A (en) 2000-06-13
DE122006000005I2 (de) 2006-11-23
NO955189L (no) 1995-12-20
DE122006000005I1 (de) 2006-08-10
AU6820894A (en) 1995-01-24
JP4662569B2 (ja) 2011-03-30
CN1129955A (zh) 1996-08-28
JPH09500267A (ja) 1997-01-14
HUT73453A (en) 1996-08-28
EP0706563B1 (en) 2004-10-06
US5677278A (en) 1997-10-14
NL300217I2 (nl) 2006-05-01
BG100236A (en) 1996-07-31
BR9407035A (pt) 1996-03-12
EP1493812A3 (en) 2006-02-08
AU681405B2 (en) 1997-08-28
ATE278777T1 (de) 2004-10-15
JP2006075173A (ja) 2006-03-23
HU9503857D0 (en) 1996-02-28
US5773586A (en) 1998-06-30
FR06C0004I2 (fr) 2006-12-29
PT706563E (pt) 2005-01-31
ES2227527T3 (es) 2005-04-01
JP3570516B2 (ja) 2004-09-29
US20090093400A1 (en) 2009-04-09
JP2009062396A (ja) 2009-03-26
FI956203A7 (fi) 1996-02-07
PL312257A1 (en) 1996-04-01
US5843883A (en) 1998-12-01
NL300217I1 (nl) 2006-04-03
KR960703433A (ko) 1996-08-17
CA2166278A1 (en) 1995-01-12
SK153295A3 (en) 1996-11-06
US6677301B1 (en) 2004-01-13
US5863767A (en) 1999-01-26
DK0706563T3 (da) 2005-01-31

Similar Documents

Publication Publication Date Title
CZ343795A3 (en) Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity
US8741841B2 (en) Fibroblast growth factor 21 proteins
AU7350000A (en) Fibroblast growth factor-like polypeptides
JP2008148711A (ja) 細胞分裂促進活性を有する短縮型インスリン様成長因子結合タンパク質
JPH10500300A (ja) 単球走化性蛋白質−４
IE913035A1 (en) Genetic material encoding new insulin-like growth factor¹binding protein (igfbp-5)
EP0556344B1 (en) New insulin-like growth factor binding protein
CA2237543A1 (en) New form of amphiregulin, methods for producing and using the same and compositions comprising the same
JPH09503661A (ja) 繊維芽細胞成長因子の表面ループ構造アナログ
US7084119B2 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity
IE913032A1 (en) New insulin-like growth factor binding protein (igfbp-4)
JPH08333394A (ja) ラット肥満遺伝子、その遺伝子産物およびその製造法
JPH11506919A (ja) 繊維芽細胞増殖因子１５
JP3534434B2 (ja) トロンボモジュリン類発現用シグナルペプチド